Subscribe
michael-vi-johnson-johnson
Michael Vi / Shutterstock
27 July 2023Liz Hockley

J&J awarded $18m in fake surgical devices case

Judge enters default judgment and permanent injunction order after defendant failed to show in court | Alleged counterfeit medical tools were being sold under Ethicon brand.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J agrees Stelara deals with generics
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
J&J settles Amgen clash over blockbuster psoriasis drug
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Medtech
Intuitive resolves robotic surgery dispute with J&J unit
10 August 2023   Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.


Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

More on this story

Americas
J&J agrees Stelara deals with generics
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
J&J settles Amgen clash over blockbuster psoriasis drug
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Medtech
Intuitive resolves robotic surgery dispute with J&J unit
10 August 2023   Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.

More on this story

Americas
J&J agrees Stelara deals with generics
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
J&J settles Amgen clash over blockbuster psoriasis drug
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Medtech
Intuitive resolves robotic surgery dispute with J&J unit
10 August 2023   Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.

More features

LSPN Europe: Navigating the EPO and lessons from the UPC’s frontline
Paul Hastings reinforces London office with high-tech patent litigator
Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings